Updated on 11 August 2014
Takeda has received USFDA approval for retreatment of MM
Singapore: Takeda Oncology company, Millennium, has received USFDA approval for Velcade (bortezomib) for the retreatment of adult patients with multiple myeloma (MM) who had previously responded to Velcade therapy and relapsed at least six months following completion of prior Velcade treatment.
The labeling update includes dosing guidelines as well as safety and efficacy findings for the use of Velcade as a single agent or Velcade in combination with dexamethasone in patients previouslytreated with Velcade. Velcade retreatment may be started at the last tolerated dose.
"For the past 11 years, Velcade has played an important role as the only therapy proven to extend overall survival for patients with newly diagnosed and relapsed multiple myeloma," said Mr Michael Vasconcelles, global head, oncology therapeutic area unit, Takeda. "With these newly approved dosing guidelines, physicians will be able to provide their patients, who have previously received Velacade, with an effective treatment extending Velacde use across the continuum of care of multiple myeloma."